MGMT and glioblastoma: All tumors evaluated had at least one molecular feature consistent with glioblastoma (EGFR amplification, TERT promoter mutation, and/or + 7/−10).2,4 No differences were noted in the frequency of homozygous CDKN2A deletion or MGMT promoter methylation, CNV level, or other molecular features (Table 1).